Research Article
A 5-Year Survival Prediction Model for Chronic Heart Failure Patients Induced by Coronary Heart Disease with Traditional Chinese Medicine Intervention
Table 1
Characteristics of patients in the training set and verification set after 5-year follow-up.
| | Variable | Training n (%) | Verification n (%) | Variable | Training n (%) | Verification n (%) | | (n = 308) | (n = 116) | (n = 308) | (n = 116) |
| | 5-year death | Clopidogre | | Yes | 158 (51.30) | 57 (49.14) | Yes | 51 (16.56) | 8 (6.90) | | No | 150 (48.70) | 59 (50.86) | No | 257 (83.44) | 108 (93.10) | | Basic characteristics | Anticoagulant | | Sex | Yes | 121 (39.29) | 27 (23.28) | | Male | 195 (63.31) | 75 (64.66) | No | 187 (60.71) | 89 (76.72) | | Female | 113 (36.69) | 41 (35.34) | Calcium antagonists | | Age (years) | Yes | 59 (19.16) | 22 (18.97) | | ＜60 | 78 (25.32) | 20 (17.24) | No | 249 (80.84) | 94 (81.03) | | ≥60 | 230 (74.68) | 96 (82.76) | Trimetazidine | | Weight (kg) | Yes | 63 (20.45) | 9 (7.76) | | ＜65 | 92 (29.87) | 33 (28.45) | No | 245 (79.55) | 107 (92.24) | | ≥65 | 216 (70.13) | 83 (71.55) | Traditional Chinese medicine | | Days in hospital | Yes | 147 (47.73) | 81 (69.83) | | ＜14 | 161 (52.27) | 72 (62.07) | No | 161 (52.27) | 35 (30.17) | | ≥14 | 147 (47.73) | 44 (37.93) | Physiological function and laboratory index | | Course (months) | Heart rate | | ＜36 | 203 (65.91) | 60 (51.72) | ＜100 | 254 (82.47) | 88 (75.86) | | ≥36 | 105 (34.09) | 56 (48.28) | ≥100 | 54 (17.53) | 28 (24.14) | | Comorbid disease | Systolic pressure | | Hypertension | ＜140 | 188 (61.04) | 60 (51.72) | | Yes | 172 (55.84) | 79 (68.10) | ≥140 | 120 (38.96) | 56 (48.28) | | No | 136 (44.16) | 37 (31.90) | Diastolic pressure | | Diabetes | ＜90 | 218 (70.78) | 65 (56.03) | | Yes | 67 (21.75) | 45 (38.79) | ≥90 | 90 (29.22) | 51 (43.97) | | No | 241 (78.25) | 71 (61.21) | NYHA_IN hospital | | Hyperlipidemia | 2 | 34 (11.04) | 10 (8.62) | | Yes | 87 (28.25) | 13 (11.21) | 3 | 183 (59.42) | 60 (51.72) | | No | 221 (71.75) | 103 (88.79) | 4 | 91 (29.55) | 46 (39.66) | | Arrhythmia | EF | | Yes | 229 (74.35) | 116 (100) | ≤40 | 125 (40.58) | 66 (56.90) | | No | 79 (25.65) | 0 (0) | ＞40 | 183 (59.42) | 50 (43.10) | | Cerebral vascular disease | LVEDD | | Yes | 187 (60.71) | 116 (100) | 35–55 | 101 (32.79) | 37 (31.90) | | No | 121 (39.29) | 0 (0) | ＜35, ＞55 | 207 (67.21) | 79 (68.10) | | Respiratory diseases | NT-proBNP | | Yes | 239 (77.60) | 116 (100) | ＜3500 | 173 (56.17) | 55 (47.41) | | No | 69 (22.40) | 0 (0) | 3500–6000 | 99 (32.14) | 50 (43.10) | | Digestive system diseases | ＞6000 | 36 (11.69) | 11 (9.48) | | Yes | 158 (51.30) | 114 (98.28) | CK | | No | 150 (48.70) | 2 (1.72) | ＜200 | 290 (94.16) | 108 (93.10) | | Kidney disease | ≥200 | 18 (5.84) | 8 (6.90) | | Yes | 146 (47.40) | 116 (100) | K | | No | 162 (52.60) | 0 (0) | 3.5-3.5 | 268 (87.01) | 104 (89.66) | | Peripheral vascular disease | ＜3.5, ＞5.5 | 40 (12.99) | 12 (10.34) | | Yes | 146 (47.40) | 116 (100) | Na | | No | 162 (52.60) | 0 (0) | 135–145 | 226 (73.38) | 91 (78.45) | | Thyroid disease | ＜135, ＞145 | 82 (26.62) | 25 (21.55) | | Yes | 132 (42.86) | 115 (99.14) | CR | | No | 176 (57.14) | 1 (0.86) | 45–100 | 237 (76.95) | 85 (73.28) | | Treatment | ＜45, ＞100 | 71 (23.05) | 31 (26.72) | | Cedilanid | ALT | | Yes | 55 (17.86) | 7 (6.03) | ＜40 | 233 (75.65) | 81 (69.83) | | No | 253 (82.14) | 109 (93.97) | ≥40 | 75 (24.35) | 35 (30.17) |
| | Digoxin | TBIL | | Yes | 161 (52.27) | 53 (45.69) | ＜20 | 173 (56.17) | 57 (49.14) | | No | 147 (47.73) | 63 (54.31) | ≥20 | 135 (43.83) | 59 (50.86) | | Diuretic | TG | | Yes | 243 (78.90) | 97 (83.62) | ＜1.7 | 200 (64.94) | 50 (43.10) | | No | 65 (21.10) | 19 (16.38) | ≥1.7 | 108 (35.06) | 66 (56.90) |
| | Spironolactone | HDLC | | Yes | 222 (72.08) | 91 (78.45) | ＜1.8 | 292 (94.81) | 109 (93.97) | | No | 86 (27.92) | 25 (21.55) | ≥1.8 | 16 (5.19) | 7 (6.03) |
| | Nitrates | LDLC | | Yes | 185 (60.06) | 49 (42.24) | ＜4.1 | 297 (96.43) | 111 (95.69) | | No | 123 (39.94) | 67 (57.76) | ≥4.1 | 11 (3.57) | 5 (4.31) |
| | ACE inhibitors/angiotensin II receptor antagonist | GLU | | Yes | 133 (43.18) | 37 (31.90) | ＜6.1 | 170 (55.19) | 46 (39.66) | | No | 175 (56.82) | 79 (68.10) | ≥6.1 | 138 (44.81) | 70 (60.34) |
| | Beta-blockers | APTT | | Yes | 176 (57.14) | 57 (49.14) | 28–45 | 228 (74.03) | 101 (87.07) | | No | 132 (42.86) | 59 (50.86) | ＜28, ＞45 | 80 (25.97) | 15 (12.93) |
| | Aspirin | HB | | Yes | 193 (62.66) | 66 (56.90) | ＜110 | 43 (13.96) | 10 (8.62) | | No | 115 (37.34) | 50 (43.10) | ≥110 | 265 (86.04) | 106 (91.38) |
|
|
